NeoGenomics to Present at the Rodman & Renshaw Healthcare Conference on November 10

Friday, November 7, 2008 General News J E 4
FT. MYERS, Fla., Nov. 7 NeoGenomics, Inc.(OTC Bulletin Board: NGNM) announced today that President and Chief ScientificOfficer, Bob Gasparini, will present at the Rodman & Renshaw 10th AnnualHealthcare Conference being held from November 10-12, 2008 at the New YorkPalace Hotel in New York City. The conference will showcase over 350 smalland microcap public life sciences and biotech companies. Gasparini and othersenior executives of attending companies will make presentations to portfoliomanagers and analysts on their business strategy and outlook. One-on-onemeetings with interested parties will also be arranged during the three-dayconference.

NeoGenomics is scheduled to present on Monday, November 10th at 5:20 PMEST. A live audio webcast of the presentation can be accessed at . A PowerPoint presentation and alink to the webcast can also be accessed through the investor relationssection of the NeoGenomics website at at the timeof the conference. The webcast will be available for three months.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratorythat specializes in cancer genetics diagnostic testing, the fastest growingsegment of the laboratory industry. The company's testing services includecytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry,morphology studies, anatomic pathology and molecular genetic testing.Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN,Irvine, CA and Fort Myers and services the needs of pathologists, oncologists,urologists, and hospitals throughout the United States. For additionalinformation about NeoGenomics, visit .

Forward Looking Statements

Except for historical information, all of the statements, expectations andassumptions contained in the foregoing are forward-looking statements. Theseforward looking statements involve a number of risks and uncertainties thatcould cause actual future results to differ materially from those anticipatedin the forward looking statements. Actual results could differ materially fromsuch statements expressed or implied herein. Factors that might cause such adifference include, among others, the company's ability to continue gainingnew customers, offer new types of tests, and otherwise implement its businessplan. As a result, this press release should be read in conjunction with thecompany's periodic filings with the SEC.Interested parties can also access additional investor relations materialfrom the American Microcap Institute at or from Hawk Associates at . An investment profile about NeoGenomics maybe found at .

SOURCE NeoGenomics, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
'Best Minds, Best Practices' in Medicine Conferenc...
Interim Analysis of Data from e-HEALING Registry o...